bumetanide has been researched along with Cerebral Infarction in 4 studies
Cerebral Infarction: The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).
| Excerpt | Relevance | Reference |
|---|---|---|
| "These data suggest that bumetanide exerts its neuroprotective and anti-edema effects partly via blockade of the perivascular pool of AQP4 and may have therapeutic potential for ischemic stroke in the clinical setting." | 3.76 | Na(+)-K (+)-2Cl (-) cotransport inhibitor attenuates cerebral edema following experimental stroke via the perivascular pool of aquaporin-4. ( Adams, ME; Amiry-Moghaddam, M; Bhardwaj, A; Froehner, SC; Migliati, ER; Ottersen, OP, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| O'Donnell, ME | 1 |
| Lam, TI | 1 |
| Tran, L | 1 |
| Anderson, SE | 1 |
| Migliati, ER | 1 |
| Amiry-Moghaddam, M | 1 |
| Froehner, SC | 1 |
| Adams, ME | 1 |
| Ottersen, OP | 1 |
| Bhardwaj, A | 1 |
| Yan, Y | 2 |
| Dempsey, RJ | 2 |
| Flemmer, A | 1 |
| Forbush, B | 1 |
| Sun, D | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study[NCT03000283] | Phase 1 | 7 participants (Actual) | Interventional | 2017-03-22 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Changes in cerebral edema (CE) as measured on CT. Goal is a -5 to -10% change in CE over time. Change will be measured both as absolute change in volume, calculated as the final volume minus the baseline volume measure and converted to a percentage of the baseline volume measure. (NCT03000283)
Timeframe: Baseline to 168 hours post-enrollment
| Intervention | percentage of change from baseline (Mean) |
|---|---|
| Conivaptan Treatment Group | -37.1 |
Cost as measured by length of stay in the neuro ICU. (NCT03000283)
Timeframe: Enrollment through hospital discharge, up to 3 weeks
| Intervention | days (Mean) |
|---|---|
| Conivaptan Treatment Group | 14.4 |
All-cause deaths during hospitalization (NCT03000283)
Timeframe: Enrollment through hospital discharge, up to 3 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Conivaptan Treatment Group | 0 |
Modified Rankin Scale (0 to 6) at discharge from the hospital. A score of 0 indicates no disability and a score of 6 indicates the patient died. Functional independence is defined as a score of 2 or less. (NCT03000283)
Timeframe: At discharge from ICU and from hospital, up to 3 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Conivaptan Treatment Group | 5 |
"Cost as measured by:~Need for external ventricular drain (EVD)/bolt or surgical procedures (craniectomy, clot evacuation,VPS) for reduction/management of CE.~Need for central venous lines, arterial lines, peripherally inserted central venous catheter (PICC) lines, tracheostomy/percutaneous endoscopic gastrostomies (PEGs).~Number of patients requiring a ventilator." (NCT03000283)
Timeframe: Baseline to 168 hours post-enrollment
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| EVD/bolt or surgical procedures | Lines or tracheostomy/PEG | Ventilator | |
| Conivaptan Treatment Group | 0 | 7 | 1 |
The number of participants with abnormal seizure activity and/or abnormal lab values and/or increase in infection rate and/or any drug-related adverse events. (NCT03000283)
Timeframe: Baseline to 168 hours post-enrollment
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Abnormal Seizure Activity | Abnormal Lab Values | Infections | Drug-related Adverse Events | |
| Conivaptan Treatment Group | 0 | 0 | 1 | 0 |
4 other studies available for bumetanide and Cerebral Infarction
| Article | Year |
|---|---|
The role of the blood-brain barrier Na-K-2Cl cotransporter in stroke.
Topics: Animals; Astrocytes; Blood-Brain Barrier; Brain Edema; Brain Ischemia; Bumetanide; Cerebral Infarcti | 2004 |
Na(+)-K (+)-2Cl (-) cotransport inhibitor attenuates cerebral edema following experimental stroke via the perivascular pool of aquaporin-4.
Topics: alpha-Synuclein; Animals; Aquaporin 4; Brain Edema; Bumetanide; Cerebral Infarction; Male; Mice; Mic | 2010 |
Inhibition of Na(+)-K(+)-Cl(-) cotransporter during focal cerebral ischemia decreases edema and neuronal damage.
Topics: Animals; Brain; Brain Edema; Brain Ischemia; Bumetanide; Cerebral Infarction; Drug Administration Sc | 2003 |
Na+-K+-Cl- cotransporter in rat focal cerebral ischemia.
Topics: Animals; Astrocytes; Autoradiography; Brain Chemistry; Brain Edema; Bumetanide; Carrier Proteins; Ce | 2001 |